Guido Lancman, MD, on Areas of Focus for Multiple Myeloma
The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.
EP: 1.Study Results Show Promise for Neoantigen Targeting Strategies Such as Peptide Vaccines
EP: 2.Recommendations for Under-Representation of African Americans in Multiple Myeloma
EP: 3.Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
EP: 4.Genetic Patterns Could Help Doctors Identify Ultra High Risk Patients of Multiple Myeloma
EP: 5.Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma
EP: 6.Guido Lancman, MD, Discusses Promising Multiple Myeloma Treatments
EP: 7.Lisa La on Areas of Interest Within Multiple Myeloma
EP: 8.Guido Lancman, MD, on Areas of Focus for Multiple Myeloma
EP: 9.Lisa La on Up-and-Coming Multiple Myeloma Research
EP: 10.Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
In an interview with CancerNetwork®, Guido Lancman, MD, hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai, highlighted which multiple myeloma patient populations he believes require further research.
Transcription:
So, there are still several populations that are not receiving the same benefit from all of these new therapies. And that's patients with high-risk cytogenetics, elderly patients, frail patients, patients with renal failure, and then of course, patients who have exhausted all therapies there’s always a need to develop new therapies for those patients.
Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
March 24th 2020The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
Recommendations for Under-Representation of African Americans in Multiple Myeloma
February 14th 2020In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them.
